1. Home
  2. MDWD vs III Comparison

MDWD vs III Comparison

Compare MDWD & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.52

Market Cap

214.9M

Sector

Health Care

ML Signal

HOLD

Logo Information Services Group Inc.

III

Information Services Group Inc.

HOLD

Current Price

$4.11

Market Cap

187.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDWD
III
Founded
2000
2006
Country
Israel
United States
Employees
N/A
1500
Industry
Medicinal Chemicals and Botanical Products
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
214.9M
187.8M
IPO Year
2013
2006

Fundamental Metrics

Financial Performance
Metric
MDWD
III
Price
$16.52
$4.11
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$36.00
$5.50
AVG Volume (30 Days)
91.0K
184.2K
Earning Date
05-20-2026
05-07-2026
Dividend Yield
N/A
4.42%
EPS Growth
N/A
216.67
EPS
N/A
0.19
Revenue
N/A
$192,745,000.00
Revenue This Year
$48.92
$3.85
Revenue Next Year
$35.04
$4.34
P/E Ratio
N/A
$21.39
Revenue Growth
N/A
4.51
52 Week Low
$14.90
$3.74
52 Week High
$22.51
$6.45

Technical Indicators

Market Signals
Indicator
MDWD
III
Relative Strength Index (RSI) 45.32 48.61
Support Level $14.90 $3.74
Resistance Level $18.49 $4.37
Average True Range (ATR) 0.63 0.13
MACD -0.07 0.02
Stochastic Oscillator 20.41 44.80

Price Performance

Historical Comparison
MDWD
III

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About III Information Services Group Inc.

Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.

Share on Social Networks: